Jyong Biotech Ltd. balance sheet MENS

Annual Quarterly

As of Dec 31, 2025, Jyong Biotech Ltd. had total assets of $20.8 million and total liabilities of $45.7 million. Stockholders' equity was negative, at -$24.9 million, because liabilities exceed assets. It held $1.2 million in cash and investments against $17.6 million of total debt, net debt of $16.4 million. The current ratio, current assets divided by current liabilities, was 0.45.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
Assets
Cash
1
Cash and investments
1
Total current assets
16
Property and equipment, net
3
Total assets
21
Liabilities and equity
Accounts payable
0
Total current liabilities
35
Total liabilities
46
Stockholders' equity
-25
Debt
Debt due within a year
15
Long-term debt
2
Lease liabilities
0
Total debt
18
Net cash
-16
Ratios
Current ratio
0.45x
Return on assets
-22.48%
Book value per share
-0.33
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MENS (Nasdaq)
Incorporated in
Cayman Islands
Headquarters
New Taipei City
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1954488

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.